France starts third clinical trial phase of its own Covid vaccine

Source : 112 Ukraine

Its key advantages will be cheap production, softer storage requirements, and lower cost
09:53, 6 July 2021

Open source

By December, France will have its own Covid vaccine. Sanofi France company has started the third phase of clinical trials, Le Figaro reports.

According to Olivier Bogillot, the head of the company, the vaccine may be available until December 2021.

Olivier Bogillon assured that unlike Pfizer-BioNTech, AstraZeneca, Moderna, and Janssen, the French vaccine does not use mRNA technology. It will be based on a recombinant protein, as in modern flu vaccinations. He noted that in combination with a special substance, the immune response will be active and will last longer.

Related: No causal link established: Pfizer comments on death of Ukrainian after vaccination

"This is a technology we use to vaccinate against influenza, a proven technology that we have been using for several years," he clarified.

Among the benefits of the French coronavirus vaccine, Bogillot named low-cost production and milder storage requirements. In addition, the low cost of the drug will help the less developed countries.

Meanwhile, India's Bharat Biotech said its Covaxin vaccine is 93.4% effective against severe Covid-19. These results were established during the third phase of drug testing.

As reported before, Janssen (Johnson & Johnson) Covid-19 vaccine for emergency medical use has been registered in Ukraine.

In addition, this month, Ukraine will get two million doses of Moderna vaccine; they will arrive from the U.S., as part of the COVAX global mechanism.

Related: Vaccination against coronavirus in the world: Map

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more